- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Mirza on the ENGOT-OV42-NSGO/AVANOVA-Triplet Trial in Recurrent Ovarian Cancer
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses the planned phase III ENGOT-OV42-NSGO/AVANOVA trial in platinum-sensitive, recurrent ovarian cancer.
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses the planned phase III ENGOT-OV42-NSGO/AVANOVA trial in platinum-sensitive, recurrent ovarian cancer.
In the phase III ENGOT-OV42-NSGO/AVANOVA trial, patients with platinum-sensitive, recurrent ovarian cancer will be randomized to 1 of 3 arms: the combination of niraparib (Zejula) and bevacizumab (Avastin), niraparib/bevacizumab plus the PD-1 inhibitor TSR-042, or standard of care chemotherapy, says Mirza. Prior data from the phase II NSGO-AVANOVA2/ENGOT-OV24 trial showed a significant improvement in progression-free survival with the combination of niraparib/bevacizumab versus niraparib alone in patients with platinum-sensitive, recurrent ovarian cancer.
Preclinical and early clinical data suggest that the addition of an immune checkpoint inhibitor to an antiangiogenic agent or PARP inhibitor could provide synergistic benefit, concludes Mirza.